Edition:
United States

Sunesis Pharmaceuticals Inc (SNSS.OQ)

SNSS.OQ on NASDAQ Stock Exchange Capital Market

1.97USD
4:00pm EDT
Change (% chg)

$-0.03 (-1.50%)
Prev Close
$2.00
Open
$2.01
Day's High
$2.01
Day's Low
$1.95
Volume
4,011
Avg. Vol
14,579
52-wk High
$4.44
52-wk Low
$1.85

Chart for

About

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia... (more)

Overall

Beta: 1.37
Market Cap(Mil.): $47.03
Shares Outstanding(Mil.): 23.51
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 89.36 16.99
EPS (TTM): -- -- --
ROI: -- 2.41 11.25
ROE: -- 3.35 15.06

BRIEF-Sunesis Pharmaceuticals reports second quarter results

* Sunesis Pharmaceuticals reports second quarter 2017 financial results and recent highlights

Jul 27 2017

BRIEF-Balyasny Asset Management reports 9.32 pct passive stake in Sunesis Pharmaceuticals

* Balyasny Asset Management reports a 9.32 percent passive stake in Sunesis Pharmaceuticals Inc as of June 23, 2017 - SEC filing Source text: (http://bit.ly/2tRWgIv) Further company coverage:

Jul 05 2017

BRIEF-Sunesis Pharmaceuticals amends loan agreement

* Sunesis Pharmaceuticals Inc - on June 30, 2017, co entered into an amendment, or amendment, to loan and security agreement dated march 31, 2016

Jun 30 2017

BRIEF-Sunesis Pharmaceuticals files for mixed shelf of up to $200 mln

* Files for mixed shelf of up to $200 million - SEC filing Source text for Eikon: Further company coverage:

Jun 08 2017

BRIEF-Sunesis Pharmaceuticals qtrly basic and diluted loss per share $0.47

* Sunesis pharmaceuticals reports first quarter 2017 financial results and recent highlights

May 08 2017

BRIEF-Sunesis Pharma announces withdrawal of European MAA for vosaroxin

* Sunesis Pharmaceuticals announces withdrawal of European Marketing Authorization Application (MAA) for vosaroxin as a treatment for relapsed/refractory AML

May 01 2017

Competitors

  Price Chg
Eisai Co., Ltd (4523.T) ¥6,025 +1.00
Johnson & Johnson (JNJ.N) $142.40 +0.36
Novartis AG (NOVN.S) CHF84.45 +0.10
Pfizer Inc. (PFE.N) $36.42 +0.18
Merck & Co., Inc. (MRK.N) $63.88 +0.13
Celgene Corporation (CELG.OQ) $121.33 -14.63

Earnings vs. Estimates